Insomnia

View All

MedTech News for Laborie, Sirtex, Paige, Neurovalens
Laborie Medical Acquired Urotronic; Sirtex’s LAVA Liquid Embolic System; Paige’s Cancer Detection in Breast Lymph Nodes; FDA Clearance to Neurovalens’s Non-Invasive Insomnia-Treating Device; Recor Medical’s Renal Denervation System; Pulsecare Medical’s nsPFA Clinical Trial Short-term Follow-up Results

Neurovalens Received US FDA Clearance for Non-Invasive Insomnia-Treating Device  On October 30, 2023, Belfast, Northern Ireland-based Neurovalens announced the US Food and Drug Administration clearance for its Modius Sleep device meant for treating chronic insomnia.  Modius has been designed to deli...

Find More

Sleep Aids Market
Sleep Aids Market: Examining Cutting-Edge Technologies and Major Breakthroughs

Sleep Aids Market: Examining Cutting-Edge Technologies and Scientific Breakthroughs Sleep can be burdensome when it disrupts daily routines, requires a significant time commitment, and is marred by sleep disorders or disturbances that affect overall well-being. In today's fast-paced world, where stress, anxiety,...

Find More

insomnia-treatment
Fewer Sleepless Nights Over, Drugs for Insomnia Treatment

“Sleep is a fundamental pillar of our overall health and well-being, and a continued lack of sleep can significantly impact many aspects of daily life”. Insomnia and its symptoms Insomnia is a common sleep-wake disorder where one has difficulty initiating or maintaining sleep or dissatisfaction with sleep q...

Find More

Pharma News and Update for Incyte and Aptose
AstraZeneca’s Farxiga; Incyte’s Jakavi; FDA Fast Track Status to HM43239 for R/R AML; Idorsia’s Insomnia Drug Quviviq; EU Approves Kymirah For Follicular Lymphoma; Perrigo Acquires HRA Pharma; Janssen Submits Marketing Authorisation Application to EMA

AstraZeneca’s Farxiga Meets Primary Endpoints in Phase 3 Heart Failure Trial Farxiga, an SGLT2 inhibitor from AstraZeneca, has shown positive results in a phase 3 Heart Failure trial, putting it back in contention with Jardiance from Boehringer Ingelheim and Eli Lilly. The DELIVER trial's top-line results demons...

Find More

pharma-news-for-gsk-idorsia-bms-novartis-lilly-cantex-viatris-biocon
GSK’s Covifenz; Idorsia’s Quviviq; GSK’s ZEJULA; EMA Expands its Nod for BMS, Eli Lilly, and Novartis Drugs; Cantex Secures Global Licence to Develop Azeliragon; Biocon Acquires Viatris’ Biosimilar Business

GSK’s Covifenz, A Plant-Based COVID Vaccine, Receives First Approval The recombinant COVID-19 vaccine developed by Medicago, now known as Covifenz, has received approval in Canada, the company's home country. Covifenz employs Coronavirus-Like Particle (CoVLP) technology, with the vaccine consisting of recombinan...

Find More

sleep-disorders-market-symptoms-risk-factors-types-and-treatment-options
Sleep Disorders: An Emerging Public Health Issue

Sleep is essential for the physical and mental health of the person. If a person didn’t get proper sleep, it might lead to many health complications. In recent time, due to various reasons such as busy work schedule, changes in sleep patterns, stress, environmental factors, certain medical conditions or medications...

Find More

Narcolepsy
Narcolepsy now a confirmed Autoimmune Disorder

The concept of sleep as a passive movement of unconsciousness has long been ruled out. But this act of rejuvenation hasn't just been restricted to the phase of resting. Usually, sleepers undergo five stages of sleep consisting of both REM (Rapid Eye Movement) and N-REM (Non- Rapid Eye Movement), each lasting f...

Find More

CRISPR
Notizia

 Vertex, CRISPR Therapeutics treated a patient using CRISPR In the very first, a patient diagnosed with Beta thalassemia was treated using CRISPR gene editing tool by Vertex and CRISPR Therapeutics.  CTX001 used to treat the disease, was extracted from hematopoietic stem cells from patients, engineered ex...

Find More